Epistemology, Ethics, and Progress in Precision Medicine

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Precision medicine seeks to tailor treatments using molecular biology.
• Predictive biomarkers are essential for guiding therapy decisions in precision medicine.
• Current research in biomarkers and diagnostics for precision medicine has not met expectations.

Purpose of the Study:

• To examine research on the excision repair cross complement group 1 (ERCC1) gene as a predictive biomarker for lung cancer therapy.
• To elucidate the epistemological and ethical obstacles in developing new precision medicines.
• To use ERCC1 as a case study for understanding challenges in biomarker development.

Main Methods:

• Review of research activities related to the ERCC1 gene.
• Analysis of the role of ERCC1 as a predictive biomarker in lung cancer.
• Examination of epistemological and ethical challenges in precision medicine development.

Main Results:

• Research into ERCC1 as a predictive biomarker for lung cancer therapy has encountered significant hurdles.
• The development of predictive biomarkers for precision medicine faces epistemological and ethical obstacles.
• The ERCC1 case study highlights the gap between expectations and reality in precision medicine research.

Conclusions:

• The development of predictive biomarkers like ERCC1 for precision lung cancer therapy is complex.
• Epistemological and ethical challenges impede the progress of precision medicine.
• Further research and ethical considerations are needed to overcome obstacles in developing effective precision medicines.